Table 1.
Demographics and patient characteristics
| Overall (N = 133) | Responder (N=67) | Nonresponder (N = 66) | p value | |
|---|---|---|---|---|
|
| ||||
| Age, median [range] | 64 [29–82] | 60 [29–82] | 68 [44–82] | < 0.001 |
| Sex | ||||
| Male | 69 | 30 | 39 | 0.14 |
| Female | 64 | 37 | 27 | |
| ECOG performance status# | ||||
| 0–1 | 108 | 58 | 50 | 0.10 |
| ≥ 2 | 22 | 7 | 15 | |
| NA | 3 | 2 | 1 | |
| Smoking status | ||||
| Never | 20 | 12 | 8 | 0.49 |
| Former/current | 113 | 55 | 58 | |
| Histology | ||||
| Adenocarcinoma | 107 | 56 | 51 | 0.10 |
| Squamous cell ca | 13 | 8 | 5 | |
| Others | 13 | 3 | 10 | |
| Stage | ||||
| Stage IV at diagnosis | 118 | 60 | 58 | 0.79 |
| Recurrent disease | 15 | 7 | 8 | |
| PD-L1 tumor proportion score# | ||||
| < 1% | 44 | 14 | 30 | 0.01 |
| 1–49% | 56 | 30 | 26 | |
| 50–90% | 15 | 10 | 5 | |
| > 90% | 10 | 8 | 2 | |
| Unknown | 8 | 5 | 3 | |
| TMB (mut/Mb)#^ | ||||
| ≤ 9.125 mut/Mb | 54 | 29 | 25 | 0.31 |
| > 9.125 mut/Mb | 42 | 18 | 24 | |
| Unknown | 37 | 20 | 17 | |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed cell death ligand-1; TMB, tumor mutational burden; mut/Mb, mutations per megabase
#
Patients with missing data, if any, are excluded from the statistical analyses
^
TMB was dichotomized at the median value (9.125 mut/Mb) of the 96 patients with available TMB data